Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | MLNR | O43193 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10729247 | 1.00 | MAPT (0.41) | MAPTNPSR1ALDH1A1HTTKDM4E | |
| SCHEMBL4800564 | 1.00 | MAPT (0.41) | MAPTNPSR1ALDH1A1HTTKDM4E | |
| SCHEMBL11125601 | 0.86 | KMT2A (0.42) | MAPTNPSR1ALDH1A1HTTKDM4E | |
| SCHEMBL6232523 | 0.85 | KDM4E (0.38) | MAPTALDH1A1HTTKDM4ECASP1 | |
| SCHEMBL7271751 | 0.85 | KDM4E (0.38) | MAPTALDH1A1HTTKDM4ECASP1 | |
| SCHEMBL6232530 | 0.85 | KDM4E (0.38) | MAPTALDH1A1HTTKDM4ECASP1 | |
| SCHEMBL10629783 | 0.83 | ALDH1A1 (0.36) | MAPTNPSR1ALDH1A1HTTKDM4E | |
| SCHEMBL11045438 | 0.80 | KMT2A (0.39) | MAPTALDH1A1HTTKDM4ECASP1 | |
| SCHEMBL11045441 | 0.80 | KMT2A (0.39) | MAPTALDH1A1HTTKDM4ECASP1 | |
| SCHEMBL10936766 | 0.74 | MAPT (0.40) | MAPTALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329756-B2 | Process for the manufacture of Isradipine | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2008-02-12 | — | — | US | claimed |
| US-20060167063-A1 | Process for the manufacture of isradipine | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2006-07-27 | — | — | US | claimed |
| WO-2005005437-A1 | AN IMPROVED PROCESS FOR THE MANUFACTURE OF ISRADIPINE. | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2005-01-20 | — | — | WO | claimed |
| US-7329756-B2 | Process for the manufacture of Isradipine | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2008-02-12 | — | — | US | disclosed |
| US-7329756-B2 | Process for the manufacture of Isradipine | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2008-02-12 | — | — | US | disclosed |
| US-20060167063-A1 | Process for the manufacture of isradipine | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2006-07-27 | — | — | US | disclosed |
| US-20060167063-A1 | Process for the manufacture of isradipine | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2006-07-27 | — | — | US | disclosed |
| WO-2005005437-A1 | AN IMPROVED PROCESS FOR THE MANUFACTURE OF ISRADIPINE. | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2005-01-20 | — | — | WO | disclosed |
| WO-2005005437-A1 | AN IMPROVED PROCESS FOR THE MANUFACTURE OF ISRADIPINE. | SHASUN CHEMICALS AND DRUGS LIMITED (IN) | 2005-01-20 | — | — | WO | disclosed |
| EP-0176956-B1 | Diaryl derivatives | BYK GULDEN LOMBERG CHEM FAB (DE) | 1994-06-15 | — | — | EP | disclosed |
| EP-0225574-B1 | NOVEL 1,4-DIHYDROPYRIDINES CONTAINING FLUORINE, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | BAYER AG (DE) | 1990-05-16 | — | — | EP | disclosed |
| EP-0189045-B1 | PYRIDOPYRIMIDINES, DIFFERENT PROCESSES FOR THEIR PREPARATION AS WELL AS THEIR USE AS MEDICAMENTS | BAYER AG (DE) | 1990-02-14 | — | — | EP | disclosed |
| US-4798840-A | Coronary-active fluorine-containing 1,4-dihydropyridines | BAYER AKTIENGESELLSCHAFT (DE) | 1989-01-17 | — | — | US | disclosed |
| WO-1988001266-A1 | NEW PIPERIDINES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1988-02-25 | — | — | WO | disclosed |
| US-4707486-A | Diaryl piperidine containing esters of 1,4-dihydropyridines and coronary therapeutic use | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1987-11-17 | — | — | US | disclosed |
| US-4707482-A | ANALGESICS, CARDIOVASCULAR DISORDERS | SANDOZ LTD. (CH) | 1987-11-17 | — | — | US | disclosed |
| EP-0225574-A1 | Novel 1,4-dihydropyridines containing fluorine, process for their preparation and their use as medicaments | BAYER AG (DE) | 1987-06-16 | — | — | EP | disclosed |
| US-4621082-A | Pyridopyrimidines, pharmaceutical compositions and use | BAYER AKTIENGESELLSCHAFT (DE) | 1986-11-04 | — | — | US | disclosed |
| EP-0189045-A2 | Pyridopyrimidines, different processes for their preparation as well as their use as medicaments | BAYER AG (DE) | 1986-07-30 | — | — | EP | disclosed |
| EP-0176956-A2 | Diaryl derivatives | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1986-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167063-A1 | Process for the manufacture of isradipine | ACMSD, AASDHPPT, DDC | MAPT 2600/4885NPSR1 1378/4885ALDH1A1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.